Is €20m A Reasonable Cost For An EU PIP? Consultation On Pediatric Rule
Executive Summary
Biosimilars, the complicated rewards system, and the costs for companies involved in carrying out a pediatric investigation plan are among the many issues discussed in the European Commission’s newly released consultation on the Paediatric Regulation nearly 10 years after it came into force.
You may also be interested in...
R&D-Based Industry Describes Practical Challenges Of EU Paediatric Regulation
From negotiating time-consuming pediatric investigation plans, to worrying about reimbursement issues, to getting things in order to secure a reward that will compensate the additional investment in pediatric research – the research-based pharmaceutical industry describes some of the practical challenges it faces in complying with the EU Paediatric Regulation.
‘Not What We Expected,’ R&D Industry Says Of ‘Onerous’ EU Paediatric Regulation
The research-based drug industry has not minced its words in describing the problems it has faced from the EU Paediatric Regulation over the past 10 years.
Pharma Attacked For “Playing The System” Of EU Pediatric Rewards
As a public consultation on the impact of the EU Paediatric Regulation comes to an end, the French drug bulletin Prescrire has attacked pharma firms for taking advantage of the rewards and incentives provided in the regulation and paying only lip service to the need for new medicines for children.